In order to strengthen its chimeric antigen receptor (CAR)-T cell therapy portfolio, Janssen has entered into an agreement with Cellular Biomedicine to develop next-generation CAR-T cell therapies for treating B-cell malignancies. The deal, that could be worth up to US$245 M, will grant Janssen exclusive global rights to develop and commercialise C-CAR039 and C-CAR066, excluding in the Greater China region. The collaboration represents an important step forward in the development of new CAR-T therapies and marks yet another move by Janssen to secure a place in the growing CAR-T therapies market.